摘要:
The inventive subject matter relates to a glutamate receptor, DNA which encodes the receptor, a transformed cell expressing the receptor, a method for producing the receptor, a method for identifying an agonist, antagonist, or allosteric modulator for glutamic acid, a method for identifying an agonist for glutamic acid, an antibody to the receptor, and processes for making glutamate receptor modulators and pharmaceutical compositions comprising said modulator.
摘要:
An agonist or antagonist of glutamic acid or an allosteric modulator is screened by reacting a glutamic acid receptor protein having the following properties with a substance binding thereto in the presence of a test substance and detecting the inhibition or promotion of the reaction:(A) it has a transmembrane domain and an intracellular domain common to those of type 4 metabotropic glutamic acid receptor protein, or(B) it has an extracellular domain by about 316 or 327 amino acid residues shorter than that of the type 4 metabotropic glutamic acid receptor protein.
摘要:
The inventive subject matter relates to novel glutamate receptors and utilization thereof; more specifically to a glutamate receptor, DNA which encodes the receptor, a transformed cell expressing the receptor, a method for producing the receptor, a method for identifying an agonist, antagonist, or allosteric modulator for glutamic acid, a method for identifying an agonist for glutamic acid, an antibody to the receptor, and processes for making glutamate receptor modulators and pharmaceutical compositions comprising said modulator.
摘要:
It is intended to disclose a glutamate sensor in taste sensation and digestion and provide techniques using the same. A glutamate-receptor protein having the following characteristics is reacted with a substance binding thereto in the presence of a test substance and thus the inhibition or acceleration of the reaction is detected to thereby search for a glutamate agonist or antagonist or an allosteric modulator: (1) having a transmembrane domain and an intracellular domain common to a type 1 metabolic glutamate receptor protein; and (2) having an extracellular domain shorter by about 409 or 481 amino acid residues than the type 1 metabolic glutamate receptor protein.
摘要:
An agonist or antagonist of glutamic acid or an allosteric modulator is screened by reacting a glutamic acid receptor protein having the following properties with a substance binding thereto in the presence of a test substance and detecting the inhibition or promotion of the reaction: (A) it has a transmembrane domain and an intracellular domain common to those of type 4 metabotropic glutamic acid receptor protein, or (B) it has an extracellular domain by about 316 or 327 amino acid residues shorter than that of the type 4 metabotropic glutamic acid receptor protein.
摘要:
As a nutritional composition and a composition for the prophylaxis or improvement of lower gastrointestinal function, which improve lower gastrointestinal function and are effective for the prophylaxis or improvement of diarrhea, gastroesophageal reflux or misswallowing caused by administration of a liquid nutritional supplement, the present invention provides a nutritional composition and a composition for the prophylaxis or improvement of lower gastrointestinal function, which comprise at least one kind selected from glutamic acid, 5′-nucleotide and a salt thereof, wherein, when glutamic acid alone is contained, the content thereof on administration is 0.0013-1.3 w/v % as free glutamic acid.
摘要:
The present invention provides an agent and a food for the prophylaxis or improvement of a functional gastrointestinal disorder, which contains, as an active ingredient, at least one kind selected from glutamic acid, 5′-nucleotide and a salt thereof.
摘要:
The present invention provides animal model of chronic stress diseases produced by feeding lysine deficient diet to the animals and a method for producing the animal model. The effect of medicine on chronic stress diseases can be judged with the animal model. Effective compounds in preventing chronic stress diseases and/or treating patients suffering from chronic stress diseases can be screened by using the animal model.
摘要:
Melatonin has an activity of treating or preventing brain edema. Thus, the invention relates to a pharmaceutical composition comprising melatonin as an active ingredient. And, the invention relates to use of melatonin in the preparation of a pharmaceutical composition comprising melatonin as an active ingredient.